In the above-mentioned study from the SCQM registry, bDMARDs other than TNFis, including interleukin-6 (IL-6) receptor inhibitors, were suggested as options for patients with RA and sSS based on their better continuation rates compared to TNFi [39]. This evidence concerns the gene IL6 and rheumatoid arthritis.